AUTHOR=Zhao Jiali , Bai Xiaohong 

TITLE=Discovery of key biomarkers in tourette syndrome by network pharmacology

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1397203

DOI=10.3389/fphar.2024.1397203

ISSN=1663-9812

ABSTRACT=<sec><title>Background</title><p>Yangxue Xifeng Decoction (YXD) has been utilized in clinical settings for the treatment of Tourette Syndrome (TS). However, the action mechanism of YXD needs further research.</p></sec><sec><title>Methods</title><p>The ingredients and targets of YXD were identified via database searches and then constructed an active ingredient-target network using Cytoscape. Pathway enrichment analysis was performed via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG). The core genes were determined by LASSO regression and SVM algorithm. Additionally, we analyzed the immune infiltration. The signaling pathways associated with core genes were investigated through KEGG and GO. We predicted the transcription factors using “RcisTarge”.</p></sec><sec><title>Results</title><p>127 active ingredients of YXD and 255 targets were obtained. TNF and the IL-17 signaling pathway were the main pathways. <italic>OPRM1</italic> and <italic>VIM</italic> were screened out as core genes, which were associated with the immune infiltration. The signaling pathways involved in <italic>OPRM1</italic> and <italic>VIM</italic> were enriched. Furthermore, remarkable correlation was found between <italic>OPRM1</italic> and <italic>VIM</italic> levels and other TS-related genes such as <italic>MAPT</italic> and <italic>MAPT</italic>.</p></sec><sec><title>Conclusion</title><p><italic>OPRM1</italic> and <italic>MAPT,</italic> and the signaling pathways are associated with TS. YXD exerts its therapeutic TS through multi-component and multi-targets including immune infiltration.</p></sec>